Skip to content

Can you take a GLP-1 while breastfeeding? What each label says

Updated Sep 27, 2026. Numbers in brackets link to the source each fact comes from.

The answer depends on which medicine and which form. Three labels tell nursing parents not to take the drug while breastfeeding. The others say the data are missing or thin and leave the decision to you and your prescriber.

The short version

Medicine What the label says about breastfeeding
Wegovy tablets Not recommended during treatment [1]
Ozempic tablets (and Rybelsus) Not recommended during treatment [4]
Foundayo Not recommended for nursing women [8]
Wegovy injection No data on milk, the baby or milk supply [3]
Ozempic injection No data on milk, the baby or milk supply [5]
Zepbound and Mounjaro One small single-dose study found little or no drug in milk [6] [7]

Why the semaglutide pills are different from the shots

Wegovy tablets and Ozempic tablets contain an ingredient called SNAC. Their labels say the effect of SNAC building up in a breastfed baby is unknown, and that semaglutide forms without SNAC exist, so they advise against breastfeeding on the tablets [2] [4]. For the injections, the labels only say that nobody has measured whether semaglutide reaches breast milk or affects the baby [3] [5].

Zepbound and Mounjaro

Both contain tirzepatide and carry the same wording. In a study where nursing women took one dose, tirzepatide in their milk was either undetectable or low compared with the dose they took [6] [7]. One dose is not the same as weekly use over months, and the label does not turn that result into a recommendation either way.

Foundayo

Foundayo, the daily orforglipron pill, is the only one of these whose label says plainly that it is not recommended for nursing women [8]. Its label also says there are no data on the drug reaching milk or affecting the baby [9].

What this means in practice

If you are breastfeeding or planning to, raise it before you start or refill, and bring the specific product name, because the pill and the shot of the same brand are labeled differently. If weight loss can wait until you stop nursing, that avoids the question. If you are already taking one of these and have just found out you are pregnant or have started breastfeeding, do not stop or switch on your own; ask the prescriber who wrote it.

Online programs do not change what the label says. A clinic that prescribes you one of these medicines should ask whether you are breastfeeding; if nobody asks, tell them.

Sources

  1. Lactation: Breastfeeding not recommended during treatment with WEGOVY tablets. (8.2) dailymed.nlm.nih.gov, read Sep 27, 2026.
  2. Because of the unknown potential for serious adverse reactions in the breastfed infant due to the possible accumulation of SNAC, and because there are alternative formulations of semaglutide that do not contain SNAC that can be used during lactation, advise patients that breastfeeding is not recommended during treatment with WEGOVY tablets. dailymed.nlm.nih.gov, read Sep 27, 2026.
  3. There are no data on the presence of subcutaneously administered semaglutide or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. dailymed.nlm.nih.gov, read Sep 27, 2026.
  4. Because of the unknown potential for serious adverse reactions in the breastfed infant due to the possible accumulation of SNAC, and because there are alternative semaglutide products that do not contain SNAC that can be used during lactation, advise patients that breastfeeding is not recommended during treatment with RYBELSUS or OZEMPIC tablets. dailymed.nlm.nih.gov, read Sep 27, 2026.
  5. There are no data on the presence of semaglutide in human milk, the effects on the breastfed infant, or the effects on milk production. dailymed.nlm.nih.gov, read Sep 27, 2026.
  6. In a single-dose clinical lactation study, the concentration of tirzepatide in breast milk was found to be either undetectable or low compared to the maternal administered dose (see Data). dailymed.nlm.nih.gov, read Sep 27, 2026.
  7. In a single-dose clinical lactation study, the concentration of tirzepatide in breast milk was found to be either undetectable or low compared to the maternal administered dose (see Data). dailymed.nlm.nih.gov, read Sep 27, 2026.
  8. FOUNDAYO is not recommended for nursing women. dailymed.nlm.nih.gov, read Sep 27, 2026.
  9. There are no data on the presence of orforglipron or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. dailymed.nlm.nih.gov, read Sep 27, 2026.

This page reports what official sources say; it is not medical advice. Medical disclaimer.